Compare
Oruka Therapeutics, Inc. vs Vanda Pharmaceuticals Inc. vs Rhythm Pharmaceuticals, Inc. vs MapLight Therapeutics, Inc.
| Latest fiscal year | Oruka Therapeutics, Inc. ORKA | Vanda Pharmaceuticals Inc. VNDA | Rhythm Pharmaceuticals, Inc. RYTM | MapLight Therapeutics, Inc. MPLT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $216.10M | $189.76M | n/a |
| Revenue growth (YoY) | n/a | +8.7% | +45.8% | n/a |
| Gross margin | n/a | n/a | 89.7% (computed) | n/a |
| Operating margin | n/a | -70.0% | -101.2% | n/a |
| Net margin | n/a | -102.0% | -103.6% | n/a |
| Net income | -$105.43M | -$220.47M | -$196.54M | -$161.15M |
| EPS (Diluted) | n/a | -$3.74 | -$3.11 | -$18.56 |
| Operating cash flow | -$88.21M | -$109.44M | -$115.67M | -$138.14M |
| Free cash flow | -$88.42M | -$110.44M | -$116.63M | -$138.61M |
| Cash & equivalents | $46.94M | $84.85M | $54.30M | $46.73M |
| Total assets | $488.62M | $488.95M | $480.20M | $479.51M |
| Total liabilities | $16.69M | $161.76M | $210.17M | $21.14M |
| Shareholders' equity | $471.93M | $327.19M | $139.07M | $458.37M |
| Return on year-end equity | -22.3% | -67.4% | -141.3% | -35.2% |
| Shares outstanding | 48.72M | 59.10M | 67.21M | 44.02M |
Revenue, most recent five fiscal years
| Fiscal year | Oruka Therapeutics, Inc. | Vanda Pharmaceuticals Inc. | Rhythm Pharmaceuticals, Inc. | MapLight Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $216.10M Ended 2025-12-31 | $189.76M Ended 2025-12-31 | n/a |
| 1 year earlier | $0 Ended 2022-12-31 | $198.77M Ended 2024-12-31 | $130.13M Ended 2024-12-31 | n/a |
| 2 years earlier | $0 Ended 2021-12-31 | $192.64M Ended 2023-12-31 | $77.43M Ended 2023-12-31 | n/a |
| 3 years earlier | $0 Ended 2020-12-31 | $254.38M Ended 2022-12-31 | $23.64M Ended 2022-12-31 | n/a |
| 4 years earlier | $0 Ended 2019-12-31 | $268.68M Ended 2021-12-31 | $3.15M Ended 2021-12-31 | n/a |